Sustanon (testosterone)

DRUG2 trials

Sponsors

Newcastle-upon-Tyne Hospitals NHS Trust, Enhanced Emirates Limited

Conditions

Duchenne Muscular DystrophySafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes

Unknown Phase

Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy

CompletedNCT02571205

Newcastle-upon-Tyne Hospitals NHS TrustDuchenne Muscular Dystrophy

Start: 2015-11-30End: 2019-03-31Updated: 2021-04-13

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling by invitationNCT07568574

Enhanced Emirates LimitedSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes

Start: 2026-03-12End: 2033-03-01Target: 60Updated: 2026-05-06

Related Papers

Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy.

2019-04-255 citations

MON-LB050 Preliminary Results from the "Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy (DMD) (NCT 02571205)"

Journal of the Endocrine Society2019-04-01